- Have any questions?
- 862-258-5500
- tdsteele@outlook.com
Regulatory expectations for nonclinical safety programs are complex, continually evolving, and often open to interpretation. Nonclinical Safety Solutions (NCSS) provides expert regulatory strategy and risk assessment services that ensure your development plans are scientifically justified, defensible, and aligned with global standards. With deep experience as both a senior industry toxicologist and a former FDA Pharmacology/Toxicology reviewer, Dr. Thomas D. Steele offers rare insight into what regulators expect—and how to position your data for successful interactions.
A strong regulatory strategy prevents delays, minimizes unexpected questions, and ensures your nonclinical package supports timely clinical progression. NCSS evaluates existing data, identifies risks or gaps, and develops a clear, cohesive plan that integrates toxicology, pharmacology, PK/ADME, and safety pharmacology into a unified safety narrative. Whether you’re preparing an IND, interpreting complex findings, or navigating new regulatory guidance, NCSS provides strategic clarity at every stage.
Effective risk assessment is equally essential. NCSS helps teams understand safety signals in the proper biological and regulatory context, determine human relevance, construct meaningful safety margins, and articulate scientifically sound rationales. This proactive approach not only strengthens your submissions but also empowers better internal decision-making throughout development.
Regulatory strategy is not simply a checklist—it requires scientific reasoning, anticipation of reviewer concerns, and a clear justification for every decision. Misinterpreting guidance or overlooking a data gap can lead to costly delays, unnecessary studies, or FDA/EMA requests that derail timelines. NCSS ensures these pitfalls are identified early and addressed proactively.
With decades of experience preparing and reviewing submissions, Dr. Steele delivers strategies that are both practical and defensible, positioning your program for smooth regulatory interactions and confident clinical progression. His combined perspectives—from both the sponsor side and inside the FDA—provide unparalleled insight into how regulators evaluate risk and what strengthens a safety argument.
If you’d like expert regulatory guidance for your program or need help evaluating risk and data gaps, we invite you to request a consultation so NCSS can assess your needs and provide clear, science-based recommendations.
A regulatory risk assessment evaluates toxicology, pharmacology, PK/ADME, and study design to identify safety risks, data gaps, and potential regulatory concerns before submission.
A strong strategy ensures studies are properly designed, sequenced, and justified—minimizing the likelihood of FDA questions, clinical holds, or requests for additional data.
Yes. NCSS assists with briefing documents, safety arguments, data summaries, and strategic positioning to support productive and efficient FDA interactions.
As early as possible—ideally during discovery or lead optimization—so that timelines, study expectations, and strategic decisions align with regulatory requirements.
NCSS evaluates findings in proper regulatory context, determines potential clinical impact, and develops mechanistic explanations or follow-up plans to mitigate risk.
Yes. NCSS provides guidance aligned with FDA, EMA, and global ICH frameworks—ensuring worldwide development strategies remain consistent and compliant.